Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Shandong Medical Imaging Research Institute Affiliated to Shandong University, Jinan, China.
Thorac Cancer. 2020 Aug;11(8):2155-2162. doi: 10.1111/1759-7714.13522. Epub 2020 Jun 30.
CalliSpheres are drug-eluting beads used for tumor artery embolization, with clinical benefits in a number of cancer types. The aim of the study was to examine the clinical benefits and complications of patients with stage II-IV lung cancer treated with CalliSpheres drug-eluting beads for embolization versus conventional vascular interventional treatment.
This was a prospective cohort study conducted from August 2018 to May 2019. The patients were grouped according to traditional bronchial arterial infusion chemotherapy (infusion group) or bronchial arterial chemoembolization with CalliSpheres drug-eluting beads loaded with adriamycin (CallisSphere group). Short-term effects, serum tumor markers, and adverse reactions during follow-up were compared between the two groups.
There were 60 participants enrolled into the study with 30 in each group including 54 men and six women, 42-78 years of age. In the CalliSphere group, compared with the infusion group, the disease control rate was 93.3% versus 73.3% (P = 0.080) and the objective remission rate (ORR) was 86.7% versus 60.0% (P = 0.039); the three- and six-month progression-free survival (PFS) and six-month overall survival (OS) were better in the CalliSphere group (three-month PFS: 96.7% vs. 73.3%, P = 0.026; six-month PFS: 87.5% vs. 57.1%, P = 0.045; six-month OS: 87.5% vs. 52.7%, P = 0.024); after treatment, the tumor markers in the CalliSphere group were lower (CEA: P < 0.001; CYFRA21-1: P = 0.014). There were no differences in adverse reactions between the two groups.
The clinical effect of bronchial arterial chemoembolization with drug-eluting beads on lung cancer is probably significant and could improve the short-term response, PFS, and OS in patients with stage IIIV lung cancer, without increasing severe adverse reactions.
SIGNIFICANT FINDINGS OF THE STUDY: The clinical effect of bronchial arterial chemoembolization with drug-eluting beads on lung cancer is probably significant and could improve the short-term response, PFS, and OS in patients with stage II-IV lung cancer, without increasing severe adverse reactions.
The ORR, PFS, OS was better in the CalliSphere group than that of infusion group; CEA and CYFRA21-1 were significant lower in CalliSphere group.
CalliSpheres 是一种用于肿瘤动脉栓塞的载药微球，在多种癌症类型中具有临床获益。本研究的目的是评估接受 CalliSpheres 载药微球栓塞与传统血管介入治疗的 II-IV 期肺癌患者的临床获益和并发症。
这是一项前瞻性队列研究，于 2018 年 8 月至 2019 年 5 月进行。患者根据传统支气管动脉灌注化疗（灌注组）或载阿霉素的 CalliSpheres 载药微球支气管动脉化疗栓塞（CallisSphere 组）分组。比较两组患者的短期疗效、血清肿瘤标志物及随访期间的不良反应。
共纳入 60 例患者，每组 30 例，包括 54 例男性和 6 例女性，年龄 42-78 岁。CalliSphere 组的疾病控制率为 93.3%，优于灌注组的 73.3%（P=0.080），客观缓解率（ORR）为 86.7%，优于灌注组的 60.0%（P=0.039）；CalliSphere 组的 3 个月和 6 个月无进展生存期（PFS）和 6 个月总生存期（OS）更好（3 个月 PFS：96.7% vs. 73.3%，P=0.026；6 个月 PFS：87.5% vs. 57.1%，P=0.045；6 个月 OS：87.5% vs. 52.7%，P=0.024）；治疗后，CalliSphere 组的肿瘤标志物水平更低（CEA：P<0.001；CYFRA21-1：P=0.014）。两组不良反应发生率无差异。
支气管动脉化疗栓塞载药微球治疗肺癌的临床效果可能显著，并可改善 III-IV 期肺癌患者的短期反应、PFS 和 OS，而不增加严重不良反应。
研究的重要发现：支气管动脉化疗栓塞载药微球治疗肺癌的临床效果可能显著，并可改善 II-IV 期肺癌患者的短期反应、PFS 和 OS，而不增加严重不良反应。
CalliSphere 组的 ORR、PFS 和 OS 均优于灌注组；CalliSphere 组的 CEA 和 CYFRA21-1 显著降低。
